IN2014DN06220A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN06220A IN2014DN06220A IN6220DEN2014A IN2014DN06220A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A IN 6220DEN2014 A IN6220DEN2014 A IN 6220DEN2014A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A
- Authority
- IN
- India
- Prior art keywords
- exons
- dystrophin gene
- human dystrophin
- oligomer
- drug
- Prior art date
Links
- 108700024394 Exon Proteins 0.000 abstract 2
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011288040 | 2011-12-28 | ||
| JP2012043092 | 2012-02-29 | ||
| PCT/JP2012/084295 WO2013100190A1 (ja) | 2011-12-28 | 2012-12-27 | アンチセンス核酸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06220A true IN2014DN06220A (sl) | 2015-10-23 |
Family
ID=48697653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6220DEN2014 IN2014DN06220A (sl) | 2011-12-28 | 2012-12-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9512424B2 (sl) |
| EP (2) | EP3594347A1 (sl) |
| JP (5) | JP6141770B2 (sl) |
| KR (2) | KR102240139B1 (sl) |
| CN (10) | CN104024414A (sl) |
| AU (2) | AU2012360702C1 (sl) |
| CA (2) | CA3132111A1 (sl) |
| ES (1) | ES2748868T3 (sl) |
| IN (1) | IN2014DN06220A (sl) |
| RU (3) | RU2619184C2 (sl) |
| TW (1) | TWI606059B (sl) |
| WO (1) | WO2013100190A1 (sl) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1766010T1 (sl) | 2004-06-28 | 2011-06-30 | Univ Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| CA2704049A1 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| PL2499249T3 (pl) | 2009-11-12 | 2019-03-29 | Univ Western Australia | Cząsteczki antysensowne i sposoby leczenia patologii |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| RU2619184C2 (ru) * | 2011-12-28 | 2017-05-12 | Ниппон Синяку Ко., Лтд. | Антисмысловые нуклеиновые кислоты |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| EA202090946A3 (ru) | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии |
| EP3662912A1 (en) | 2013-03-15 | 2020-06-10 | Sarepta Therapeutics, Inc. | Improved dosages of eteplirsen for treating duchenne muscular dystrophy |
| PL3118311T3 (pl) | 2014-03-12 | 2019-09-30 | Nippon Shinyaku Co., Ltd. | Antysensowny kwas nukleinowy |
| WO2015178277A1 (ja) * | 2014-05-19 | 2015-11-26 | 神戸天然物化学株式会社 | ＣＤ４４遺伝子のバリアントエクソンのスキッピングを誘導し、正常型ＣＤ４４ｍＲＮＡの発現を増加させる核酸医薬 |
| CN106661577B (zh) | 2014-06-17 | 2020-05-12 | 日本新药株式会社 | 反义核酸 |
| EP3208277A4 (en) | 2014-10-14 | 2018-06-13 | Ajinomoto Co., Inc. | Morpholino oligonucleotide manufacturing method |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| KR102473431B1 (ko) * | 2015-09-15 | 2022-12-01 | 니뽄 신야쿠 가부시키가이샤 | 안티센스 핵산 |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| EP3359523A4 (en) | 2015-10-09 | 2019-07-24 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| JP7008642B2 (ja) * | 2016-05-24 | 2022-01-25 | サレプタ セラピューティクス， インコーポレイテッド | オリゴマー調製のためのプロセス |
| MA45155A (fr) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| KR20190024977A (ko) | 2016-06-30 | 2019-03-08 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 |
| WO2018107003A1 (en) * | 2016-12-08 | 2018-06-14 | The Board Of Regents Of The University Of Texas System | Dmd reporter models containing humanized duschene muscular dystrophy mutations |
| MX2019006882A (es) | 2016-12-19 | 2019-08-16 | Sarepta Therapeutics Inc | Conjugados de oligomeros de omision de exon para distrofia muscular. |
| HUE059905T2 (hu) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exonátugró oligomerkonjugátumok izomdisztrófiára |
| BR112019012651A2 (pt) * | 2016-12-19 | 2020-01-28 | Sarepta Therapeutics Inc | conjugados de oligômero de salto de éxon para distrofia muscular |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| EP3687577A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20210104759A (ko) * | 2018-12-13 | 2021-08-25 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근 이영양증을 위한 엑손 스키핑 올리고머 접합체 |
| AU2018454784A1 (en) * | 2018-12-25 | 2021-08-05 | National Center Of Neurology And Psychiatry | Method for inducing muscular cells using cells in spot urine |
| IL293997A (en) | 2019-12-19 | 2022-08-01 | Nippon Shinyaku Co Ltd | Antistrand nucleic acids that allow exon skipping |
| KR20220122673A (ko) * | 2019-12-26 | 2022-09-02 | 니뽄 신야쿠 가부시키가이샤 | 엑손 50의 스키핑을 유도하는 안티센스 핵산 |
| BR112023021849A2 (pt) | 2021-04-30 | 2023-12-19 | Sarepta Therapeutics Inc | Métodos de tratamento para distrofia muscular |
| JPWO2022239863A1 (sl) | 2021-05-13 | 2022-11-17 | ||
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| WO2023282345A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 腎毒性軽減剤 |
| JPWO2023282344A1 (sl) | 2021-07-08 | 2023-01-12 | ||
| IL310001A (en) | 2021-07-08 | 2024-03-01 | Nippon Shinyaku Co Ltd | sediment suppressant |
| CA3226365A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP4389893A1 (en) | 2021-08-21 | 2024-06-26 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| WO2023171820A1 (ja) * | 2022-03-11 | 2023-09-14 | 日本新薬株式会社 | キャリアペプチドが連結された核酸 |
| WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398378B2 (ja) | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
| JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体，デバイス及び医薬組成物 |
| SK282843B6 (sk) | 1993-07-13 | 2002-12-03 | Rhone-Poulenc Rorer S. A. | Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom |
| US6727355B2 (en) * | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| EP1191097A1 (en) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| CA2796924C (en) | 2002-11-25 | 2016-12-13 | Nonprofit Organization Translational Research Organization Of Duchenne Muscular Dystrophy | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| AU2003225410A1 (en) * | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| SI1766010T1 (sl) | 2004-06-28 | 2011-06-30 | Univ Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo |
| WO2006038608A1 (ja) | 2004-10-05 | 2006-04-13 | Nippon Shinyaku Co., Ltd. | オリゴ二本鎖ｒｎａ及び医薬組成物 |
| JP2008538500A (ja) * | 2005-04-22 | 2008-10-30 | アカデミス ツィーケンホイス ライデン | ＳＲタンパク質の結合に対する干渉とＲＮＡ二次構造に対する干渉による、ｍＲＮＡ前駆体におけるエクソン認識の調節 |
| WO2006129594A1 (ja) | 2005-05-30 | 2006-12-07 | Nippon Shinyaku Co., Ltd. | 核酸含有複合体製剤の製造方法 |
| US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| WO2008096690A1 (ja) | 2007-02-05 | 2008-08-14 | Nippon Shinyaku Co., Ltd. | ポリエチレングリコール誘導体 |
| CA2704049A1 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| PT2607484E (pt) * | 2008-10-27 | 2016-03-09 | Academisch Ziekenhuis Leiden | Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne |
| AU2010239779A1 (en) | 2009-04-24 | 2011-11-17 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
| US20120270930A1 (en) * | 2009-10-29 | 2012-10-25 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Methods and compositions for dysferlin exon-skipping |
| PL2499249T3 (pl) * | 2009-11-12 | 2019-03-29 | Univ Western Australia | Cząsteczki antysensowne i sposoby leczenia patologii |
| WO2011150408A2 (en) | 2010-05-28 | 2011-12-01 | Avi Biopharma, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| JP5593949B2 (ja) | 2010-08-17 | 2014-09-24 | 横河電機株式会社 | プログラマブルロジックコントローラ |
| RU2619184C2 (ru) * | 2011-12-28 | 2017-05-12 | Ниппон Синяку Ко., Лтд. | Антисмысловые нуклеиновые кислоты |
-
2012
- 2012-12-27 RU RU2014130600A patent/RU2619184C2/ru active
- 2012-12-27 CN CN201280064590.3A patent/CN104024414A/zh not_active Withdrawn
- 2012-12-27 IN IN6220DEN2014 patent/IN2014DN06220A/en unknown
- 2012-12-27 CN CN202311738073.6A patent/CN117721110A/zh active Pending
- 2012-12-27 RU RU2017114509A patent/RU2651468C1/ru active
- 2012-12-27 CN CN201910167665.4A patent/CN110055244A/zh not_active Withdrawn
- 2012-12-27 ES ES12861221T patent/ES2748868T3/es active Active
- 2012-12-27 KR KR1020207001044A patent/KR102240139B1/ko active IP Right Grant
- 2012-12-27 WO PCT/JP2012/084295 patent/WO2013100190A1/ja active Application Filing
- 2012-12-27 CA CA3132111A patent/CA3132111A1/en active Pending
- 2012-12-27 CN CN201910167466.3A patent/CN110079525A/zh active Pending
- 2012-12-27 CN CN201810389950.6A patent/CN108611349A/zh active Pending
- 2012-12-27 CN CN202410462539.2A patent/CN118207212A/zh active Pending
- 2012-12-27 CA CA2861247A patent/CA2861247C/en active Active
- 2012-12-27 AU AU2012360702A patent/AU2012360702C1/en active Active
- 2012-12-27 KR KR1020147018749A patent/KR102071729B1/ko active IP Right Grant
- 2012-12-27 CN CN201711192063.1A patent/CN107881175B/zh active Active
- 2012-12-27 EP EP19182708.8A patent/EP3594347A1/en active Pending
- 2012-12-27 JP JP2013551878A patent/JP6141770B2/ja active Active
- 2012-12-27 CN CN201810389742.6A patent/CN108588073A/zh active Pending
- 2012-12-27 CN CN201810389811.3A patent/CN108486116A/zh active Pending
- 2012-12-27 EP EP12861221.5A patent/EP2799548B1/en active Active
- 2012-12-27 CN CN201910167486.0A patent/CN110055243B/zh active Active
- 2012-12-27 US US14/368,307 patent/US9512424B2/en active Active
- 2012-12-28 TW TW101150922A patent/TWI606059B/zh active
-
2016
- 2016-10-31 US US15/339,069 patent/US9890381B2/en active Active
-
2017
- 2017-05-08 JP JP2017092674A patent/JP6734222B2/ja active Active
-
2018
- 2018-01-12 US US15/870,308 patent/US10781448B2/en active Active
- 2018-03-21 RU RU2018109906A patent/RU2681470C1/ru active
- 2018-09-14 AU AU2018229530A patent/AU2018229530B2/en active Active
-
2020
- 2020-03-09 JP JP2020039457A patent/JP7038365B2/ja active Active
- 2020-08-21 US US16/999,695 patent/US20210222169A1/en active Pending
-
2021
- 2021-12-20 JP JP2021206326A patent/JP2022058379A/ja not_active Withdrawn
-
2023
- 2023-12-26 JP JP2023218763A patent/JP2024038103A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06220A (sl) | ||
| PH12016501761A1 (en) | Antisense nucleic acids | |
| EP2828275A4 (en) | SYNTHESIS OF 3-O-FUCOSYLLACTOSE TYPE TRISACCHARIDE AND ITS INTERMEDIATES | |
| LT3378862T (lt) | Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui | |
| HK1173015A1 (en) | Provision of contextual advertising | |
| IL225769A0 (en) | Piperidine-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
| EP2544584A4 (en) | ON THE BODY WORN LIFE SIGNAL MONITOR | |
| EP2545161A4 (en) | ENTEROBACTER SP. 638 AND METHOD FOR ITS USE | |
| IL235349A0 (en) | Therapeutic use of Chardonnay grape products | |
| ZA201307956B (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
| IT1401855B1 (it) | Apparecchiatura per il trattamento di un prodotto. | |
| IL225815A0 (en) | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | |
| EP2750715A4 (en) | IDENTIFICATION OF SMALL MOLECULES THAT ENHANCE THE EXON THERAPEUTIC JUMP | |
| IN2014CN00795A (sl) | ||
| IN2015DN01524A (sl) | ||
| IL225406A0 (en) | Therapeutic applications of smad7 | |
| EP2971156A4 (en) | Genes and gene signatures for diagnosis and treatment of melanoma | |
| EP3052654A4 (en) | Identification of structurally similar small molecules that enhance therapeutic exon skipping | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| EP2661434A4 (en) | NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER | |
| ZA201306420B (en) | Regulated gene expression systems and constructs thereof | |
| HK1217689A1 (zh) | 及其生物活性類似物的合成 | |
| EP2738251A4 (en) | NEW GENE FOR INDUCING EXTENSION OF ROOTS OR FOR IMPROVING BIOMASS AND USE THEREOF | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy |